摘要：8090...

林中小屋

共计5668台/制动控制模块软件存偏差沃尔沃旗下部分车型遭召回_我的网站

相约星期六

A | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。

[ 资讯] 6月27日，浙江豪情汽车制造有限公司、大庆沃尔沃汽车制造有限公司和沃尔沃汽车销售（上海）有限公司根据《缺陷汽车产品召回管理条例》和《缺陷汽车产品召回管理条例实施办法》的要求，向国家市场监督管理总局备案了召回计划，决定自即日起召回以下车辆。

召回范围：召回编号S2025M0109V：生产日期从2024年4月8日至2025年6月11日的部分国产沃尔沃XC60插混版，共计3378辆；生产日期为2022年7月25日的部分沃尔沃C40(参数|询价)，共计1辆；生产日期为2023年8月9日的部分沃尔沃XC40，共计1辆。召回编号S2025M0110V：生产日期从2024年5月6日至2025年6月11日的部分沃尔沃S90插混版，共计1520辆；生产日期从2021年8月4日至2022年10月24日的部分沃尔沃S60插混版，共计4辆。召回编号S2025M0111V：生产日期从2024年4月25日至2025年6月11日的部分沃尔沃XC90插混版，共计764辆。召回原因：本次召回范围内部分车辆，由于制动控制模块的软件偏差，当插电式混合动力车（PHEV）在“B”挡驱动模式或纯电动车（BEV）在“单踏板驾驶”模式，在不踩制动踏板且持续下坡滑行超过1分30秒的情况下，车辆可能失去制动功能，存在安全隐患。解决办法：浙江豪情汽车制造有限公司，大庆沃尔沃汽车制造有限公司和沃尔沃汽车销售（上海）有限公司将委托沃尔沃汽车授权经销商，为召回范围内的车辆免费升级制动控制模块的软件，以消除安全隐患。浙江豪情汽车制造有限公司，大庆沃尔沃汽车制造有限公司和沃尔沃汽车销售（上海）有限公司将以挂号信等方式，通知相关用户。沃尔沃汽车授权经销商也将主动联系相关车主，安排召回事宜。用户可通过手机和固定电话，拨打沃尔沃汽车客服中心电话：10108666进行咨询。此外，也可登录市场监管总局召回中心网站www.samrdprc.org.cn、www.recall.org.cn，关注微信公众号（SAMRDPRC），了解更多信息，反映缺陷线索。（文/ 周易）

。